← Human Trials & Peer-Reviewed Studies
Improved Treatment and Monitoring of Alzheimer's Disease
Plain-language guide to NCT07135245: phase 2 randomized trial of Semaglutide, 180 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07135245
- Phase
- phase 2
- Status
- not yet recruiting
- Start
- 2026-01-01
- Completion (planned or actual)
- 2030-09-30
- Participants
- 180 (estimated)
- Design
- randomized, quadruple-blind, treatment
- Conditions studied
- Alzheimer Disease (AD)
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
The trial (phase 2) is built around Semaglutide.
In Denmark 90,000 live with dementia and life expectancy after dementia diagnosis is 5 to 8 years.
It had three arms (groups): Intervention - semaglutide only (experimental), Control (placebo comparator) and Intervention - combination (experimental).
A control group treated with placebo and no further intervention.
The registry classes the interventions as drug and other.
Who Took Part
180 planned participants were the target.
It was open to people of any sex.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: MRI scan of the brain with coronal sections showing substance loss (atrophy) of the medial part of the temporal lobe compatible with Alzheimer's disease.
How the Study Was Run
The set-up was randomized, parallel-group and quadruple-blind.
Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The Semaglutide group and the comparison group ran side by side rather than switching.
Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.
Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.
It started in 2026-01-01 with completion listed for 2030-09-30.
Its stated primary purpose is treatment.
What Was Measured
Primary outcome: The Montreal Cognitive Assessment (time frame: At inclusion, and 52 and 78 weeks).
It also tracked 12 secondary outcomes, for example Measurement of β-Amyloid1-42, Measurement of Tau, MRI scan of the brain, PET scan of the brain, Clinical Dementia Rating scale - Sum of Boxes and Symbol Digit Modalities Test.
What This Means in Plain Language
Put simply, this is a phase 2, randomized trial of Semaglutide in 180 people.
Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.